Syndax Pharmaceuticals SNDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$243.25M+26.6% | -$285.42M+10.5% | -$311.58M-4.9% | -$334.99M-26.8% | -$331.2M-37.6% | ||
| $49.18M+10.5% | $47.5M+10.4% | $48.55M+24.3% | $48.4M+36.6% | $44.51M+32.4% | ||
| -$278.16M+2.9% | -$322.98M-17.5% | -$310.88M-20.1% | -$302.67M-25.5% | -$286.52M-39.8% | ||
| $234.28M— | $290.04M— | -$60.52M— | -$46.1M— | —— | ||
| $20.66M-94.1% | $13.68M-96.1% | $355.18M+34.3% | $352M+33.8% | $352.13M+33.5% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Syndax Pharmaceuticals generate?
- Syndax Pharmaceuticals (SNDX) generated -$278.2M in operating cash flow over the trailing twelve months.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
